Two cancer treatments, previously only available to patients through the Cancer Drugs Fund (CDF), will now be routinely available on the NHS, UK's National Institute for Health and Care Excellence (NICE) has announced.
NICE has approved bosutinib for leukaemia and pemetrexed for lung cancer for routine use on the NHS because the companies that market them lowered their prices.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Aug 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Aug 16
